MTOR and cancer: These features captured by the tumoroid platform include resistance to chemotherapeutic agents carboplatin and paclitaxel, increased expression of cancer stem-like markers, increased migration and invasion, and activation of EMT, Wnt/β-catenin, and PI3K/Akt/mTOR pathways.